Lumito (LUMITO) Q2 2026 earnings summary

Executive summary

• Strong commercial and scientific momentum in Q2 2026, with increased international visibility and strategic collaborations driving commercialization of SCIZYS platform.

• First CRO-related revenues achieved, validating the business model and commercial potential.

• Strengthened financial platform through a rights issue, securing resources for continued commercialization.

Financial highlights

• Net sales for Q2 2026 were 0 TSEK (0 TSEK Q2 2025); H1 2026 net sales reached 78 TSEK (0 TSEK H1 2025).

• Net loss after tax for Q2 2026 was -10,059 TSEK (-11,275 TSEK Q2 2025); H1 2026 net loss was -20,555 TSEK (-23,078 TSEK H1 2025).

• Cash flow from operations in Q2 2026 was -4,159 TSEK (-7,374 TSEK Q2 2025); H1 2026 was -10,891 TSEK (-14,158 TSEK H1 2025).

• Cash and cash equivalents at period end were 3,318 TSEK (7,178 TSEK Q2 2025).

• Equity at period end was 53,801 TSEK (69,714 TSEK Q2 2025); equity ratio 81% (79%).

Outlook and guidance

• Management expresses confidence in continued growth, leveraging strengthened scientific evidence, strategic partnerships, and new capital.

• Rights issue completed post-period, raising 15 MSEK, with potential for an additional 15 MSEK in early 2027 via warrants.

• Ongoing focus on converting SCIZYS interest into recurring business and long-term customer relationships.